AXQ Capital LP Buys Shares of 50,448 Elanco Animal Health Incorporated $ELAN

Key Points

• AXQ Capital LP initiated a new Elanco Animal Health position, purchasing 50,448 shares worth approximately $1.24 million in the second quarter. Institutional investors collectively own 97.48% of the company.
• Analysts remain broadly positive, with Elanco receiving a “Moderate Buy” consensus rating and an average price target of $29.09; UBS and KeyCorp recently raised their targets to $33 and $30, respectively.
• Elanco exceeded quarterly expectations, reporting adjusted EPS of $0.34 versus the $0.27 consensus and revenue of $1.37 billion, up 10.2% year over year. Company directors and executives have also recently purchased shares.

AXQ Capital LP bought a new stake in Elanco Animal Health Incorporated (NYSE:ELAN - Free Report) in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund bought 50,448 shares of the company's stock, valued at approximately $1,242,000.

Other institutional investors and hedge funds also recently made changes to their positions in the company. Parallel Advisors LLC grew its holdings in shares of Elanco Animal Health by 5.9% during the 4th quarter. Parallel Advisors LLC now owns 7,060 shares of the company's stock valued at $160,000 after purchasing an additional 392 shares during the last quarter. Sapient Capital LLC grew its stake in shares of Elanco Animal Health by 0.3% during the second quarter. Sapient Capital LLC now owns 128,573 shares of the company's stock worth $3,164,000 after buying an additional 420 shares during the last quarter. Lazard Asset Management LLC grew its stake in shares of Elanco Animal Health by 0.6% during the fourth quarter. Lazard Asset Management LLC now owns 72,065 shares of the company's stock worth $1,631,000 after buying an additional 425 shares during the last quarter. Northwestern Mutual Investment Management Company LLC increased its holdings in shares of Elanco Animal Health by 0.4% during the fourth quarter. Northwestern Mutual Investment Management Company LLC now owns 111,166 shares of the company's stock worth $2,516,000 after buying an additional 428 shares in the last quarter. Finally, Meeder Advisory Services Inc. increased its holdings in shares of Elanco Animal Health by 4.8% during the fourth quarter. Meeder Advisory Services Inc. now owns 11,235 shares of the company's stock worth $254,000 after buying an additional 510 shares in the last quarter. Institutional investors own 97.48% of the company's stock.

Analyst Upgrades and Downgrades

A number of analysts have recently commented on the company. KeyCorp boosted their price target on Elanco Animal Health from $29.00 to $30.00 and gave the stock an "overweight" rating in a report on Thursday, August 6th. Morgan Stanley raised their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the company an "equal weight" rating in a report on Wednesday, July 22nd. Wall Street Zen downgraded shares of Elanco Animal Health from a "strong-buy" rating to a "buy" rating in a research report on Sunday, May 24th. UBS Group boosted their target price on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a "buy" rating in a report on Thursday, August 6th. Finally, Piper Sandler reaffirmed an "overweight" rating on shares of Elanco Animal Health in a research note on Monday, June 29th. One equities research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Elanco Animal Health presently has an average rating of "Moderate Buy" and a consensus target price of $29.09.

Elanco Animal Health Stock Up 0.2%

ELAN stock opened at $24.48 on Friday. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58. The firm has a market capitalization of $12.23 billion, a PE ratio of -59.71, a P/E/G ratio of 1.83 and a beta of 1.68. The stock's 50 day moving average is $24.64 and its 200-day moving average is $23.97. Elanco Animal Health Incorporated has a twelve month low of $17.51 and a twelve month high of $27.98.

Elanco Animal Health (NYSE:ELAN - Get Free Report) last announced its quarterly earnings data on Wednesday, August 5th. The company reported $0.34 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.27 by $0.07. Elanco Animal Health had a positive return on equity of 8.13% and a negative net margin of 3.96%.The firm had revenue of $1.37 billion during the quarter, compared to the consensus estimate of $1.31 billion. During the same quarter in the prior year, the company earned $0.26 EPS. The business's revenue for the quarter was up 10.2% on a year-over-year basis. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. Sell-side analysts expect that Elanco Animal Health Incorporated will post 1.12 EPS for the current fiscal year.

Insider Transactions at Elanco Animal Health

In other news, Director Michael Harrington purchased 5,000 shares of the company's stock in a transaction dated Wednesday, August 12th. The shares were purchased at an average price of $21.82 per share, with a total value of $109,100.00. Following the transaction, the director directly owned 131,451 shares of the company's stock, valued at approximately $2,868,260.82. This represents a 3.95% increase in their ownership of the stock. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CFO Robert Vanhimbergen acquired 4,200 shares of the stock in a transaction that occurred on Friday, August 7th. The stock was purchased at an average price of $23.08 per share, for a total transaction of $96,936.00. Following the completion of the purchase, the chief financial officer directly owned 137,516 shares in the company, valued at $3,173,869.28. This trade represents a 3.15% increase in their position. Additional details regarding this purchase are available in the official SEC disclosure. Over the last 90 days, insiders purchased 63,198 shares of company stock valued at $1,473,109. 1.14% of the stock is currently owned by insiders.

About Elanco Animal Health

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco's portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source